PerkinElmer (NYSE:PKI)‘s stock had its “buy” rating restated by analysts at Stifel Nicolaus in a report issued on Thursday, AnalystRatings.com reports.
Several other equities analysts have also issued reports on PKI. Bank of America raised shares of PerkinElmer from a “neutral” rating to a “buy” rating and set a $105.00 price target for the company in a report on Thursday, September 26th. UBS Group decreased their price target on shares of PerkinElmer from $101.00 to $92.00 and set a “neutral” rating for the company in a report on Friday, October 18th. BMO Capital Markets boosted their price target on shares of PerkinElmer from $50.00 to $52.00 and gave the company an “outperform” rating in a report on Wednesday, November 6th. Raymond James reissued an “average” rating and issued a $51.00 price target on shares of PerkinElmer in a report on Tuesday, November 5th. Finally, ValuEngine lowered shares of PerkinElmer from a “buy” rating to a “hold” rating in a report on Wednesday, July 31st. Ten equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. PerkinElmer has an average rating of “Hold” and an average target price of $73.59.
Shares of PerkinElmer stock opened at $90.52 on Thursday. The firm has a fifty day moving average of $85.66 and a two-hundred day moving average of $88.12. The stock has a market capitalization of $10.10 billion, a price-to-earnings ratio of 25.07, a PEG ratio of 1.65 and a beta of 1.29. PerkinElmer has a 52 week low of $71.83 and a 52 week high of $103.00. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.97 and a current ratio of 1.30.
In related news, Director Alexis P. Michas sold 2,000 shares of the company’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $82.56, for a total value of $165,120.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.80% of the stock is currently owned by corporate insiders.
Several institutional investors have recently bought and sold shares of the company. Massachusetts Financial Services Co. MA boosted its stake in shares of PerkinElmer by 6.5% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 4,457,732 shares of the medical research company’s stock worth $379,665,000 after buying an additional 272,310 shares during the last quarter. Ropes Wealth Advisors LLC acquired a new position in shares of PerkinElmer during the 3rd quarter worth about $73,000. Tower Research Capital LLC TRC boosted its stake in shares of PerkinElmer by 30.6% during the 3rd quarter. Tower Research Capital LLC TRC now owns 3,773 shares of the medical research company’s stock worth $321,000 after buying an additional 885 shares during the last quarter. First Trust Advisors LP boosted its stake in shares of PerkinElmer by 106.7% during the 3rd quarter. First Trust Advisors LP now owns 283,694 shares of the medical research company’s stock worth $24,162,000 after buying an additional 146,417 shares during the last quarter. Finally, Bartlett & Co. LLC boosted its stake in shares of PerkinElmer by 430.1% during the 3rd quarter. Bartlett & Co. LLC now owns 493 shares of the medical research company’s stock worth $42,000 after buying an additional 400 shares during the last quarter. Institutional investors own 95.16% of the company’s stock.
PerkinElmer Company Profile
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.
Featured Article: How to Invest in the Dividend Aristocrat Index
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.